ORIC Pharmaceuticals Adds Richard Scheller, Ph.D., Former CSO of Genentech, to its Board of Directors
South San Francisco, CA – March 9, 2015 – ORIC Pharmaceuticals, Inc., a privately-held company dedicated to the discovery and development of novel therapeutics for the treatment of cancer, announced today that Richard Scheller, Ph.D. will be joining its Board of Directors. Dr. Scheller spent 14 years leading research efforts that have yielded multiple FDA-approved drugs as chief scientific officer at Genentech and as executive vice president after its acquisition by the Roche Group.
“Richard Scheller will bring a wealth of experience from Genentech rooted in a deep understanding of basic science and drug development,” said Peter Svennilson, ORIC’s acting chief executive officer. “His insights and strategic advice will be substantial contributions to the growth of ORIC.”
Dr. Scheller noted that “ORIC has an outstanding team of academic founders and scientists who are dedicated to addressing the complexities of treatment-resistant cancers. Their culture of scientific rigor will be critical to discovering novel therapies that provide more meaningful treatment results for patients.”
Dr. Scheller is currently the chief scientific officer and head of therapeutic development at 23andMe. He serves as a trustee of Caltech and on the board of Xenon Pharmaceuticals Inc. Prior to joining Genentech, Dr. Scheller was a professor at Stanford University and an investigator with the Howard Hughes Medical Institute at Stanford University Medical Center. His work has been recognized by the Albert Lasker Basic Medical Research Award, the Kavli Prize in Neuroscience, and the 1997 US National Academy of Sciences Award in Molecular Biology, among other honors. He is also a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences.
About ORIC Pharmaceuticals
ORIC is a privately-held pharmaceutical company dedicated to discovering and developing novel therapies for treatment-resistant cancers. While recent advances with targeted therapeutics have extended prognoses in many disease settings, cancers often develop resistance to these drugs. ORIC has assembled a world-class scientific team dedicated to the discovery of therapies that can meaningfully improve clinical outcomes for these patients.
ORIC was founded by two world-class experts in oncology, Dr. Charles Sawyers and Dr. Scott Lowe, who have strong records of discovering innovative treatments and targets for cancer. ORIC has assembled a team of highly-experienced scientists who are executing multiple drug discovery strategies targeting the mechanisms that allow tumors to become resistant to current therapies. In addition, the scientific team has unparalleled access to the operational expertise of advisors who have devoted their careers to oncology drug development. Finally, the Company is supported by investors with extensive experience in both drug development and the financing of life science companies.
ORIC Pharmaceuticals is headquartered in South San Francisco, California. For more information, please visit the Company’s website at http://www.oricpharma.com.